Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 9, 2021

Pfizer trials lower Covid-19 vaccine dose in children

The Phase II/III trial will enrol up to 4,500 children at more than 90 sites, with the first results expected in September.

Pfizer has selected a lower dose of its Covid-19 vaccine, co-developed with BioNTech, for assessment in Phase II/III clinical trial involving children aged under 12.

The company chose 10µg and 3µg doses of the Covid-19 vaccine based on safety, tolerability and immune response data gathered from 144 children in a Phase I trial.

In the Phase II/III trial, up to 4,500 children will be enrolled at more than 90 sites in the US, Finland, Poland and Spain.

Participants aged five to 11 years will receive a 10µg dose of the vaccine, while those aged six months to five years will receive a 3µg dose.

In a statement, Pfizer clinical research and development senior vice-president Dr Bill Gruber said: “We take a deliberate and careful approach to help us understand the safety and how well the vaccine can be tolerated in younger children.

“Children younger than 12 make up a significant portion of the total global population and can develop Covid-19 disease, and also can spread the virus to others.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“If successful, we believe vaccinating children will help further protect our communities and contribute to the evolving herd immunity.”

Results from five to 11-year-old subjects are expected to be available in September and will be used to seek emergency use authorisation. Data from children aged two to five years is set to follow soon after.

Pfizer anticipates data from participants aged six months to two years in October or November.

The company’s Covid-19 vaccine already holds emergency use authorisation for children aged 12 to 15 in the US, Europe and Canada.

This age group received a 30μg dose of the vaccine. Data demonstrated a 100% vaccine efficacy in participants with or without prior Covid-19 infection and strong antibody responses.

Last month, a Public Health England (PHE) study found that the Covid-19 vaccine was effective against the B.1.617.2 variant of SARS-CoV-2 first identified in India and now detected worldwide.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU